Actuate Therapeutics announced promising preclinical results for its oral elraglusib tablet, which significantly inhibited tumor growth and enhanced immune response in an aggressive melanoma model. The drug increased key immune cells and reduced tumor-suppressing cells, indicating potential to improve treatment for difficult cancers. A Phase 1/2 clinical trial is planned to start in early 2027, initially targeting metastatic melanoma patients. This development could lead to new, more effective therapies for hard-to-treat cancers.
Actuate Therapeutics' new melanoma drug data provide context for health sector trends. For readers following health stocks, 121 of 150 US health-sector stocks on Pluang rose, 23 fell as of Nov 04, 2026 19:41 WIB. Notable movers include THC at USD 281.00 (+5.37%, 100% sell activity), TLRY at USD 2.77 (+4.53%, 96% sell), and VRTX at USD 554.38 (+4.45%, 58% sell / 42% buy).
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
